Rajkumar Patil V - 27 Jul 2026 Form 4/A - Amendment Insider Report for OKYO Pharma Ltd (OKYO)

Reporting relationship: Chief Scientific Officer
Issuer ticker: OKYO
Reported as of: 27 Jul 2026
Net transaction value: +$5,011
SEC form: 4/A - Amendment
Accepted by SEC: 07 Aug 2026, 16:15:29 UTC
Original report date: 29 Jul 2026
Prior SEC filing: 29 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Raj Patil

Key filing fact

Rajkumar Patil V filed Form 4/A - Amendment for OKYO Pharma Ltd (OKYO) on 07 Aug 2026.

Key facts

This page summarizes Rajkumar Patil V's Form 4/A - Amendment filing for OKYO Pharma Ltd (OKYO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 07 Aug 2026, 16:15.

Change

Previous filing in this sequence was filed on 29 Jul 2026.
Current net transaction value: +$5,011.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0002124067 Primary reporting owner

Patil Rajkumar V.

Relationship: Chief Scientific Officer
Address: 14-15 CONDUIT ST, LONDON, UNITED KINGDOM
Signature: /s/ Raj Patil
Signature date: 07 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OKYO transaction

COMMON STOCK

Purchase

Transaction value: $5,011
Shares: +3,363
Change %: +20%
Price: $1.49
Shares after: 20,030
Date: 27 Jul 2026
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

SEC remarks

This Form 4/A amends the Form 4 filed on July 29, 2026 solely to correct the transaction code associated with this open market purchase. No other reported transactions are affected by this amendment.